RADAR-CNS (Remote Assessment of Disease and Relapse – Central Nervous System) aims to transform patient care through remote assessment using wearable technologies such as smartphones or fitness trackers.  The project will develop the technology to identify which clinical or physiological features – biosignatures – can be measured remotely to predict relapse or deterioration.  

To achieve this, we are creating a pipeline for developing, testing and implementing remote measurement technologies for depression, multiple sclerosis (MS) and epilepsy.  Patients will be involved at each stage of development. It will include a generic data management and modelling infrastructure applicable to other mental and physical disorders.  It will be designed with the flexibility to be sustainable alongside future technological developments.

We will anticipate and solve any potential problems with using these technologies by consulting patients, clinicians, regulators and healthcare providers throughout the project.

We bring together an international consortium of academic and EFPIA members who are leaders in the fields of depression, multiple sclerosis and epilepsy.  We also deliver clinical expertise and access to patient cohorts in each disease area.  This is combined with leading technical and methodological expertise in the disciplines required to develop and implement remote measurement technologies.